This database contains 472 studies, archived under the term: "Pharmaceutical Interventions"
Click here to filter this large number of results.
Effect of compound Polygonum multiflorum extract on Alzheimer’s disease
Objective: To observe the clinical effect of compound Polygonum multiflorum extract on Alzheimer’s disease (AD).; Methods: We collected 209 AD patients, among whom 120 were treated with compound Polygonum multiflorum extract as a treatment group, 60 were treated with Polygonum multiflorum extract as a Chinese herb control group, and 29 were treated with Naofukang as […]
A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer’s disease
Akhondzadeh, Shahin,
Shafiee Sabet, Mehdi,
Harirchian, Mohammad Hossein,
Togha, Mansoreh,
Cheraghmakani, Hamed,
Razeghi, Soodeh,
Hejazi, Seyyed Shamssedin,
Yousefi, Mohammad Hossein,
Alimardani, Roozbeh,
Jamshidi, Amirhossein,
Rezazadeh, Shams-Ali,
Yousefi, Aboulghasem,
Zare, Farhad,
Moradi, Atbin,
Vossoughi, Ardalan
Rationale: There is increasing evidence to suggest the possible efficacy of Crocus sativus (saffron) in the management of Alzheimer’s disease (AD).; Objective: The purpose of the present investigation was to assess the efficacy of C. sativus in the treatment of patients with mild-to-moderate AD.; Methods: Fifty-four Persian-speaking adults 55 years of age or older who […]
Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial
Akhondzadeh, S.,
Sabet, M. Shafiee,
Harirchian, M. H.,
Togha, M.,
Cheraghmakani, H.,
Razeghi, S.,
Hejazi, S. Sh,
Yousefi, M. H.,
Alimardani, R.,
Jamshidi, A.,
Zare, F.,
Moradi, A.
What Is Known: Herbal medicines have been used in the treatment of behavioural and psychological symptoms of dementia but with variable response. Crocus sativus (saffron) may inhibit the aggregation and deposition of amyloid β in the human brain and may therefore be useful in Alzheimer’s disease (AD).; Objective: The goal of this study was to […]
Safety and tolerability of galantamine in possible Alzheimer’s disease with or without cerebrovascular disease and vascular dementia in Thai patients
Senanarong, Vorapun,
Poungvarin, Niphon,
Phanthumchinda, Kammant,
Thavichachart, Nuntika,
Chankrachang, Siwaporn,
Praditsuwan, Rungnirund,
Nidhinandana, Samart
The purpose of this study was to explore factors that influence the clinical safety and tolerability associated with galantamine administration in Thai Alzheimer’s disease patients with or without cerebrovascular disease and vascular dementia. This was an analysis of previous study. Tolerability and safety profile were analyzed according to sex, age, body weight, Thai mental state […]
Controlled study of auricular point taping and pressing therapy for treatment of vascular dementia
Chen, Qi,
Huang, Hong-min,
Xu, Yu-jiao,
Lu, Rui-li,
Zhou, Xiao-hui,
Zhou, Cheng
Objective: To assess the therapeutic effect of auricular point taping and pressing therapy on vascular dementia (VD).; Methods: One hundred and eighty cases of vascular dementia were randomly divided into an auricular point taping and pressing group and a western medicine group, 90 cases in each group. The auricular point taping and pressing group was […]
Ibuprofen treatment modifies cortical sources of EEG rhythms in mild Alzheimer’s disease
Babiloni, Claudio,
Frisoni, Giovanni B.,
Del Percio, Claudio,
Zanetti, Orazio,
Bonomini, Cristina,
Cassetta, Emanuele,
Pasqualetti, Patrizio,
Miniussi, Carlo,
De Rosas, Mario,
Valenzano, Anna,
Cibelli, Giuseppe,
Eusebi, Fabrizio,
Rossini, Paolo M.
Objective: Non-steroidal anti-inflammatory drugs such as ibuprofen have a protective role on risk of Alzheimer’s disease (AD). Here we evaluated the hypothesis that long-term ibuprofen treatment affects cortical sources of resting electroencephalographic (EEG) rhythms in mild AD patients.; Methods: Twenty-three AD patients (13 treated AD IBUPROFEN; 10 untreated AD PLACEBO) were enrolled. Resting EEG data […]
Alzheimer’s Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results
Background: The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) was designed to address whether non-steroidal anti-inflammatory drugs (NSAIDs) can prevent or delay the onset of Alzheimer’s disease (AD).; Methods: ADAPT was a randomized, double-placebo-controlled, multicenter chemoprevention trial conducted at six U.S. dementia research clinics. At entry, participants were required to test “normal” on a battery of […]